Amgen Faces Scrutiny Over Continued Drug Recalls

Amgen is experiencing ongoing Class II nationwide recalls for specific lots of its Sensipar and Corlanor tablets, initiated in early June 2026. These recalls are due to FDA-identified current good manufacturing practice deviations and the presence of foreign substances. The persistent nature of these issues raises questions about Amgen's operational oversight and management of regulatory risk, potentially impacting patient safety.